Long-term prognosis and risk factors for cardiac adverse events in patients with chronic systolic heart failure due to hypertension

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 5, 2008, Pages 280-288

  Szyguła Jurkiewicz, Bozena ^a,c   Owczarek, Aleksander ^b   Duszańska, Agata ^a   Sikora, Jacek ^a   Lekston, Andrzej ^a   Pudlo, Robert ^a   Wojnicz, Romuald ^a   Poloński, Lech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Department of Applied Informatics ^*  (Poland)

^c III Kat I Kliniczny O   (Poland)

Author keywords

Arterial hypertension; Chronic systolic heart failure; Outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIGOXIN; FUROSEMIDE; METOPROLOL; SPIRONOLACTONE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; SYMPTOMATOLOGY; SYSTOLIC HEART FAILURE;

ADULT; CHRONIC DISEASE; DEPRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 45249094541     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.388     Document Type: Article

References (41)

1. Jaarsma T, Haaijer-Ruskamp FM, Sturm H, et al. Management of heart failure in The Netherlands. Eur J Hear Fail. 2005; 7: 371-375.
2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003; 348: 2007-2018.
3. Muntwyler J, Abetel G, Gruner C, et al. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002; 23: 1861-1866.
4. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83: 778-786.
5. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-Heft VA Cooperative Studies Group. Circulation. 1993; 87 (Suppl): V15-V16.
6. De Groote P, Dragorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol. 2004; 43: 1584-1589.
7. The task force for the diagnosis and treatment of chronic heart failure. ESC guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22: 1527-1560.
8. Braunwald E, Zipes DP, Libby P. Heart disease. Philadelphia, Saunders Company, 2005.
9. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 561-571.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psych. 1960; 23: 56-62.
11. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol. 2000; 53: 229-235.
12. Frimm CC, Soufen HN, Koike MK, et al. The long-term outcome of patients with hypertensive cardiomyopathy. J Hum Hypert. 2005; 19: 393-400.
13. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077-1084.
14. Alla F, Briançon S, Juillière Y, et al. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J. 2000; 139: 895-904.
15. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic con gestive heart failure secondary to idiopatic dilated or ischemic cardiomyopathy. Am J Cardiol. 1987; 59: 634-638.
16. Matthews JN, Altman DG. Statistic notes. Compare effect sizes not p values. BMJ. 1996; 313: 808.
17. Altman DG, Bland JM. Statistic notes. Absence of evidence is not evidence of absence. Br Med J. 1995; 311: 485.
18. Easterbrook PJ, Berlin JA. Publications bias in clinical research. Lancet. 1991; 337: 867-872.
19. Berlin JA, Colin BB, Louis TA. An assessment of publications bias using a sample of published clinical trials. J Am Stat Assoc. 1989; 84: 381-392.
20. Alehagen U, Dahlstrom U, Lindahl TL, et al. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost. 2004; 92: 1250-1258.
21. Kaneko K, Kanda T, Yamauchi Y, et al. C-reactive protein in dilated cardiomyopathy. Cardiology. 1999; 91: 215-219.
22. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Hear Fail. 2002; 4: 331-336.
23. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol. 2002; 15: 1405-1409.
24. Rumsfeld JS, Rumsfeld JS, Havranek EP, et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol. 2003; 42: 1811-1817.
25. Sullivan MD, Levy WC, Crane BA, et al. Usefulness of depression to predict time to combined end point of transplant or death for outpatiens with advanced heart failure. Am J Cardiol. 2004; 94: 1577-1580.
26. Havranek EP, Ware M, Lowes BD. Prevalence of depression in patients with congestive heart failure. Am J Cardiol. 1999; 84: 348-350.
27. Skotzko C, Krichten C, Zietowski G, et al. Depression is common and precludes accurate assessment of functional status in elderly patients with congestive heart failure. J Cardiac Fail. 2000; 6: 300-305.
28. Joynt KE, Whellan DJ, O'Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Cardiac Fail. 2004; 10: 258-271.
29. Thomas SA, Friedmann E, Khatta M. Depression in patients with heart failure. AACN Clinical Issues. 2003; 14: 3-12.
30. Friedman MM, Griffin JA. Relationship of physical symptoms and physical functioning to depression in patients with heart failure. Heart Lung. 2001; 30: 98-104.
31. Meluzin J, Spinarowa L, Bakala J, et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion: a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J. 2001; 22: 340.
32. Alam M, Wardell J, Andersson E, et al. Characteristics of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue imaging in healthy subjects. J Am Soc Echocardiogr. 1999; 12: 618.
33. Spinarova L, Meluzin J, Oman J, et al. Right ventricular dysfunction in chronic heart failure patients. Eur J Heart Fail. 2005; 7: 485-489.
34. Di Salvo TG, Mahier M, Semigran MJ, et al. Preserved right ventricular ejection fracion predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995; 25: 1143-1152.
35. De Groote P, Millaire A, Foucher-Hossein A, et al. Right ventricular ejection fraction is an independent predictor of survival of patients with moderate heart failure. J Am Coll Cardiol. 1998; 32: 948-954.
36. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997; 95: 1247-1252.
37. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996; 98: 2854-2865.
38. Kubota T, McTiernan CF, Frye CS. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor alpha. Circ Res. 1997; 81: 627-635.
39. Marcucci R, Gori AM, Giannotti F, et al. Markers of hypercoagulability and inflammation predicts mortality in patients with heart failure. J Thromb Haemost. 2006; 4: 1017-1022.
40. Maeda K, Tsutamoto, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 1587-1593.
41. Tarnow I, Falk T, Tidholm A, et al. Haemostatic biomarkers in dogs with chronic congestive heart failure. J Vet Intern Med. 2007; 21: 451-457.